NSE DRREDDY · BSE 500124 · Biotechnology & Drugs · NIFTY 50
Dr Reddy's Laboratories Share Price
₹1,200.10
▼ −₹11.51 · 0.95%
NSE · as of 24 Sep 2026, 9:29 AM · BSE ₹1,198.60
Today's range
₹1,196.85Low₹1,214.35High
52-week range
₹1,080.05Low · 23 Jul 2026₹1,414.40High · 29 Jun 2026
Dr Reddy's Laboratories Overview
Where the price stands, how it has moved and how it sits against its averages.
Dr Reddy's Laboratories shares last traded at ₹1,200.10 on the NSE, down 0.95% on the day. That is 15.2% below the 52-week high of ₹1,414.40 and 11.1% above the 52-week low of ₹1,080.05. The stock trades at 35.07× earnings, below the sector average of 36.50. Its market value is ₹1,00,040 Cr.
Price returns
1 Day▼ −0.95%
5 Days▲ +6.25%
This month▲ +4.92%
3 Months▼ −8.82%
6 Months▼ −6.88%
This year▼ −4.73%
1 Year▼ −7.43%
Against the market: 1 Month ▲ +6.09% · 3 Months ▼ −6.19% · 6 Months ▼ −6.33% · This year ▲ +8.50% · 1 Year ▲ +1.57%
Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST).
Moving averages — price is above 4 of 6
- 300-day average₹1,249.49 ▼ price 4.0% below
- 100-day average₹1,241.31 ▼ price 3.3% below
- Today's price₹1,200.10
- 5-day average₹1,181.86 ▲ price 1.5% above
- 50-day average₹1,178.03 ▲ price 1.9% above
- 20-day average₹1,168.36 ▲ price 2.7% above
- 10-day average₹1,165.88 ▲ price 2.9% above
Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.
Dr Reddy's Laboratories Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
33,700
5,655
4,196
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹33,700 Cr | ▲ +3.2% | ₹4,196 Cr | 12.5% | ₹50.35 | ₹8.00 |
| FY 2025 | ₹32,644 Cr | ▲ +16.5% | ₹5,655 Cr | 17.3% | ₹67.79 | ₹8.00 |
| FY 2024 | ₹28,011 Cr | ▲ +13.5% | ₹5,578 Cr | 19.9% | ₹66.92 | ₹8.00 |
| FY 2023 | ₹24,670 Cr | ▲ +14.5% | ₹4,507 Cr | 18.3% | ₹54.18 | ₹8.00 |
| FY 2022 | ₹21,545 Cr | ▲ +13.1% | ₹2,183 Cr | 10.1% | ₹26.19 | ₹6.00 |
| FY 2021 | ₹19,048 Cr | ▲ +8.7% | ₹1,952 Cr | 10.2% | ₹23.09 | ₹5.00 |
| FY 2020 | ₹17,517 Cr | — | ₹2,026 Cr | 11.6% | ₹24.35 | ₹5.00 |
8,828
8,100
1,593
444
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹8,100 Cr | ▲ +7.3% | ₹444 Cr | 5.5% | ₹5.33 |
| Q4 FY26 | ₹7,546 Cr | ▼ −13.8% | ₹221 Cr | 2.9% | ₹2.65 |
| Q3 FY26 | ₹8,753 Cr | ▼ −0.8% | ₹1,210 Cr | 13.8% | ₹14.52 |
| Q2 FY26 | ₹8,828 Cr | ▲ +3.0% | ₹1,347 Cr | 15.3% | ₹16.17 |
| Q1 FY26 | ₹8,572 Cr | ▲ +0.5% | ₹1,418 Cr | 16.5% | ₹17.02 |
| Q4 FY25 | ₹8,528 Cr | ▲ +1.8% | ₹1,593 Cr | 18.7% | ₹19.10 |
| Q3 FY25 | ₹8,381 Cr | ▲ +4.3% | ₹1,414 Cr | 16.9% | ₹16.94 |
| Q2 FY25 | ₹8,038 Cr | — | ₹1,256 Cr | 15.6% | ₹15.07 |
Balance sheet — FY26
Owes (liabilities)Shareholders' equity
35%
65%
- Total assets₹58,123 Cr
- Total liabilities₹20,232 Cr
- Shareholders' equity₹37,892 Cr
- Total debt₹7,734 Cr
- Cash & investments₹8,909 Cr
- Current ratio1.80×
- Revenue growth, 5 yr12.09% a year
- EPS growth, 5 yr16.87% a year
- Operating margin (TTM)9.09%
- Net margin (TTM)9.58%
Cash flow — FY26
Operating activities
▲ ₹5,674 Cr
Investing activities
▼ −₹6,549 Cr
Financing activities
▲ ₹829 Cr
Free cash flow
▲ ₹1,833 Cr
Net change in cash
▲ ₹78 Cr
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 17,517.00 | 19,047.50 | 21,545.20 | 24,669.70 | 28,011.10 | 32,643.90 | 33,700.20 |
| Cost of revenue | 6,012.60 | 6,564.70 | 7,997.20 | 8,304.80 | 8,939.80 | 10,783.40 | 13,036.30 |
| Gross profit | 11,504.40 | 12,482.80 | 13,548.00 | 16,364.90 | 19,071.30 | 21,860.50 | 20,663.90 |
| Operating expenses | 16,203.00 | 16,402.20 | 18,942.70 | 19,449.80 | 21,548.00 | 25,800.50 | 29,305.50 |
| Operating income | 1,314.00 | 2,645.30 | 2,602.50 | 5,219.90 | 6,463.10 | 6,843.40 | 4,394.70 |
| Depreciation | 1,163.10 | 1,228.80 | 1,165.20 | 1,250.20 | 1,470.00 | 1,703.70 | 2,058.90 |
| Profit before tax | 1,885.70 | 2,883.50 | 3,061.40 | 6,048.50 | 7,201.00 | 7,679.50 | 5,392.70 |
| Tax | −136.20 | 963.20 | 883.30 | 1,541.20 | 1,623.10 | 1,954.30 | 1,235.10 |
| Net profit | 2,026.00 | 1,951.60 | 2,182.50 | 4,507.30 | 5,577.90 | 5,655.10 | 4,196.00 |
| EPS (₹) | 24.35 | 23.09 | 26.19 | 54.18 | 66.92 | 67.79 | 50.35 |
| Dividend per share (₹) | 5.00 | 5.00 | 6.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 23,225.30 | 26,616.80 | 29,746.90 | 32,285.10 | 38,863.80 | 49,426.60 | 58,123.40 |
| Current assets | 12,599.10 | 14,550.30 | 17,782.30 | 20,425.50 | 24,805.30 | 25,018.10 | 30,179.30 |
| Cash & short-term investments | 2,561.60 | 3,438.70 | 4,420.70 | 6,164.20 | 8,131.30 | 5,775.90 | 8,908.70 |
| Inventory | 3,506.70 | 4,541.20 | 5,088.40 | 4,867.00 | 6,355.20 | 7,689.00 | 8,237.50 |
| Property, plant & equipment | 5,214.30 | 5,686.10 | 6,166.50 | 6,629.40 | 7,599.70 | 9,697.80 | 11,538.00 |
| Total liabilities | 7,626.50 | 8,975.10 | 10,534.50 | 8,999.00 | 10,609.00 | 15,877.00 | 20,231.90 |
| Current liabilities | 7,214.10 | 8,103.80 | 9,765.80 | 8,572.10 | 9,588.00 | 13,033.80 | 16,747.40 |
| Total debt | 2,210.20 | 3,030.80 | 3,384.50 | 1,347.20 | 2,002.00 | 4,676.60 | 7,734.10 |
| Total equity | 15,598.80 | 17,641.70 | 19,212.40 | 23,286.10 | 28,254.80 | 33,549.60 | 37,891.50 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 2,984.10 | 3,570.30 | 2,810.80 | 5,887.50 | 4,543.30 | 4,642.80 | 5,673.70 |
| From investing | −492.30 | −2,266.00 | −2,638.70 | −4,137.30 | −4,028.30 | −5,807.70 | −6,549.30 |
| From financing | −2,515.90 | −29.80 | −242.20 | −2,686.10 | −376.30 | 1,891.10 | 829.00 |
| Capital expenditure | −611.50 | −1,256.10 | −1,904.90 | −1,886.60 | −2,743.50 | −3,439.80 | −3,840.50 |
| Dividends paid | −391.60 | −414.70 | −414.60 | −497.90 | −664.80 | −666.20 | −665.90 |
| Net change in cash | −26.60 | 1,285.80 | 3.20 | −907.30 | 132.80 | 748.60 | 77.50 |
What Analysts Say
36 analysts
Recommendations from 36 analysts who cover Dr Reddy's Laboratories.
Hold
average rating 2.97 on a 1–5 scale
Strong buyBuyHoldSellStrong sell
▲ 13 bullish (36.1%) · 9 hold (25.0%) · ▼ 14 bearish (38.9%)
Votes
Strong Buy
5 (14%)
Buy
8 (22%)
Hold
9 (25%)
Sell
11 (31%)
Strong Sell
3 (8%)
How the votes changed
| Rating | 3M ago | 2M ago | 1M ago | 1W ago | Now | 3-month change |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | ▼ −1 |
| Buy | 12 | 9 | 9 | 8 | 8 | ▼ −4 |
| Hold | 9 | 10 | 9 | 9 | 9 | — |
| Sell | 7 | 10 | 11 | 11 | 11 | ▲ +4 |
| Strong Sell | 4 | 4 | 4 | 3 | 3 | ▼ −1 |
Analyst ratings are opinions, not a guarantee of returns.
Dr Reddy's Laboratories vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield | Rating |
|---|---|---|---|---|---|---|---|---|---|
| Dr Reddy's Laboratories | ₹1,200.10 | ▼ −0.95% | ₹1,00,040 Cr | 35.07 | 2.66 | 16.74% | 9.58% | 0.66% | This stock |
| Sun Pharmaceutical Industries | ₹1,850.30 | ▼ −0.79% | ₹4,43,938 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% | Moderately Bearish |
| Divi's Laboratories | ₹9,633.00 | ▲ +0.38% | ₹2,55,726 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% | Bullish |
| Torrent Pharmaceuticals | ₹4,935.50 | ▼ −0.89% | ₹1,87,724 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% | Bullish |
| Cipla | ₹1,401.10 | ▲ +1.53% | ₹1,13,189 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% | Neutral |
| Zydus Lifesciences | ₹1,186.70 | ▲ +1.47% | ₹1,18,374 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% | Bullish |
Rating = the data provider's overall technical view of each peer. Company names link to their own pages.
Dr Reddy's Laboratories Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Dr Reddy's LaboratoriesBenchmarkComfortable → stretched
Valuation Is the price reasonable?
P/E (TTM)Price ÷ yearly earnings per share
35.07
▼ 4% below the sector average of 36.50
P/E, 12-month rangeLow 16.87 · high 41.38
74%
Today's P/E sits 74% of the way from its low to its high
P/BPrice ÷ book value per share
2.66
P/SPrice ÷ sales per share
3.04
P/CFPrice ÷ cash flow per share
19.03
Profitability Of every ₹100 of sales, how much is kept?
Gross marginKept after the cost of goods
61.43%
▼ below its 5-yr average of 65.10%
Operating marginKept after running costs
9.09%
▼ below its 5-yr average of 18.16%
Pre-tax marginKept before tax
12.16%
▼ below its 5-yr average of 20.90%
Net marginKept as profit
9.58%
▼ below its 5-yr average of 15.75%
Returns & efficiency How well does it use its money?
Return on equityProfit on shareholders' money
11.75%
▼ below its 5-yr average of 16.74%
Return on assetsProfit on everything it owns
7.73%
▼ below its 5-yr average of 11.49%
Return on investmentProfit on long-term capital
10.79%
▼ below its 5-yr average of 15.96%
Growth Is the business getting bigger?
Revenue — last 12 months
−0.9%
▼ shrinking
Revenue — 3 yr, a year
+11.0%
▲ growing
Revenue — 5 yr, a year
+12.1%
▲ growing
EPS — last 12 months
−43.2%
▼ shrinking (off the scale)
EPS — 3 yr, a year
−2.4%
▼ shrinking
EPS — 5 yr, a year
+16.9%
▲ growing
Dividend — 3 yr, a year
0.0%
▲ growing
Book value — 5 yr, a year
+16.4%
▲ growing
Financial strength Can it pay its bills and debts?
Debt to equityBorrowings for every ₹1 of shareholders' money
0.20×
Current ratioShort-term assets for every ₹1 due within a year
1.80×
Quick ratioLike the current ratio, without inventory
1.31×
Interest coverOperating profit ÷ interest to pay
8.39×
Payout ratioShare of profit paid as dividend
15.91%
Per share What each share stands for
EPS (TTM)
₹38.67
Book value
₹455.04
Cash flow
₹63.63
Dividend
₹8.00
Revenue
₹398.75
The share price is 2.64× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
All 110 metrics from the data provider
Valuation
P/E excluding extraordinary items, most recent fiscal year24.05
Current Dividend Yield - Common Stock Primary Issue, LTM0.66
Price to Book - most recent fiscal year2.66
P/E Basic excluding extraordinary items - TTM35.07
P/E including extraordinary items - TTM31.32
P/E excluding extraordinary items low, trailing 12 months16.87
Price to Tangible Book - most fiscal year3.89
Dividend Yield - 5 Year Average0.70
Price to sales - most recent fiscal year2.99
Dividend Yield - indicated annual dividend divided by closing price0.66
Price to Cash Flow per share - trailing 12 month19.03
Price to Free Cash Flow per Share - most recent fiscal year86.43
P/E Normalized, most recent fiscal year23.63
P/E excluding extraordinary items high, trailing 12 months41.38
P/E excluding extraordinary items, most recent fiscal year quarter31.32
Price to sales - trailing 12 month3.04
Net Debt, LFY−11,746.00
Per share
Dividend Per Share - 5 year average7.60
Cash Flow per share - trailing 12 month63.63
Cash Flow per share - most recent fiscal year74.60
EPS including extraordinary items - trailing 12 month38.67
EPS including extraordinary items - most recent fiscal year50.35
EBITD per share - trailing 12 month65.92
Revenue/share - trailing 12 month398.75
EPS excluding extraordinary items - trailing 12 month38.67
EPS Basic excluding extraordinary items - most recent fiscal year50.41
EPS Basic excluding extraordinary items - trailing 12 month38.69
Book value per share - most recent fiscal year455.05
Dividend per share - most recent fiscal year8.00
Revenue/share - most recent fiscal year404.40
EPS Normalized - most recent fiscal year51.25
Book value (tangible) per share - most recent fiscal year311.11
Dividends per share - trailing 12 month8.00
EPS excluding extraordinary items - most recent fiscal year50.35
Cash per share - most recent fiscal year106.99
Margins
Operating margin - trailing 12 month9.09
Gross Margin - 5 year average65.10
Operating margin - 1st historical fiscal year13.04
Operating Margin - 5 year average18.16
Net Profit Margin % - 1st historical fiscal year12.34
Gross Margin - 1st historical fiscal year61.32
Net Profit Margin % - trailing 12 month9.58
Net Profit Margin - 5 year average15.75
Pretax Margin - 5 year average20.90
Pretax margin - 1st historical fiscal year16.00
Pretax margin - trailing 12 month12.16
Free Operating Cash Flow/Revenue, 5 Year Average4.86
Gross Margin - trailing 12 month61.43
Growth
EPS Change %, TTM over TTM−43.24
Revenue growth rate, 5 year12.09
EPS growth rate, 5 year16.87
Revenue Change % - most recent quarter 1 year ago−5.51
Growth rate% - dividend, 3 year0.00
Growth rate% - EPS, 3 year−2.41
Revenue/share (5 yr growth)12.04
Free Operating Cash Flow, 5 Year CAGR−9.28
Tangible Book Value, Total Equity, 5 Year CAGR13.83
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR4.81
Capital Spending growth rate, 5 year25.05
Revenue Change %, TTM over TTM−0.87
Growth rate% - Revenue, 3 year10.96
Book value per share growth rate, 5 year16.41
EPS Change % - most recent quarter 1 year ago−68.68
Net Profit Margin growth rate, 5 year4.12
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR8.38
Total Debt, 5 Year CAGR20.61
Financial strength
Free Cash Flow - most recent fiscal year11,673.00
LT debt/equity - most recent fiscal year0.03
Quick ratio - most recent fiscal year1.31
Payout ratio - trailing 12 month20.72
Current ratio - most recent fiscal year1.80
Current EV/Free Cash Flow, LFY58.51
Total debt/total equity - most recent fiscal year0.20
Net Interest coverage - trailing 12 month8.39
Payout ratio - most recent fiscal year15.91
Returns & efficiency
Return on average equity - 5 year average16.74
Net Income/employee - trailing 12 month11,56,428.00
Revenue/employee - most recent fiscal year1,23,73,630.00
Return on investment - most recent fiscal year10.79
Return on average assets - most recent fiscal year7.73
Receivables turnover - most recent fiscal year3.52
Inventory turnover - most recent fiscal year1.64
Revenue/employee - trailing 12 month1,20,71,020.00
Return on average assets - 5 year average11.49
Net Income/employee - most recent fiscal year15,26,537.00
Asset turnover - most recent fiscal year0.63
Return on average equity - most recent fiscal year11.75
Return on investment - 5 year average15.96
Price & volume
Market Cap1,00,565.93
52 week Low Date23 Jul 2026
Price - 1 Day % Change0.02
Relative (S&P500) price percent change - 13 week−6.19
Avg trading volume last 10 days1.89
Price - 13 week price percent change−8.82
Price - 52 week price percent change−7.43
Avg Trading Volume Last 3 months43.44
Price - 5 Day % Change6.25
Price % Change Month To Date4.92
Relative (S&P500) price percent change - 04 week6.09
52 week High Date29 Jun 2026
Price - 26 week price percent change−6.88
PDATE23 Sep 2026
Price - YTD price percent change−4.73
Relative (S&P500) price percent change - 52 week1.57
NPRICE1,211.20
Relative (S&P500) price percent change - 26 week−6.33
52 week Low1,101.00
52 week High1,414.90
Beta0.44
Relative (S&P500) price percent change - Year to Date8.50
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
₹8.00
₹8.00
- Dividend yield0.66%
- Payout ratio15.91%
- 5-year average dividend₹7.60 a share
- Latest dividend₹8.00 per share · 10 Jul 2026
Corporate calendar
- Upcoming · BoardQuarterly Results
- MeetingAnnual General Meeting
- BoardQuarterly Results
- Dividend₹8.00 per share · 800% · Final dividend
- BoardAudited Results
- BoardQuarterly Results
- BoardQuarterly Results
- MeetingAnnual General Meeting
- Dividend₹8.00 per share · 800% · Final dividend
Show 12 older events
- BoardAudited Results, Dividend & Others
- BoardQuarterly Results
- BoardQuarterly Results
- SplitStock split — face value ₹5 → ₹1
- MeetingPostal Ballot
- MeetingAnnual General Meeting
- Dividend₹40.00 per share · 800% · Final dividend
- MeetingPostal Ballot
- MeetingPostal Ballot
- Dividend₹40.00 per share · 800% · Final dividend
- Dividend₹30.00 per share · 600% · Final dividend
- Dividend₹25.00 per share · 500% · Final dividend
About Dr Reddy's Laboratories
Biotechnology & Drugs
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Key people
- Kallam Satish ReddyExecutive Chairman of the Board
- Gunupati Venkateswara PrasadExecutive Co-Chairman, Managing Director
- Erez IsraeliChief Executive Officer
- Mannam Venkata NarasimhamChief Financial Officer
- Milan KalawadiaChief Executive Officer, North America
- M. V. RamanaChief Executive Officer - Global Generics
Company facts
- NSE symbolDRREDDY
- BSE code500124
- ISININE089A01031
- IndustryBiotechnology & Drugs
- IndexNIFTY 50, NIFTY 500
- Market cap₹1,00,040 Cr
- Revenue (FY26)₹33,700 Cr
- Net profit (FY26)₹4,196 Cr
In the News
Recent headlines about Dr Reddy's Laboratories — they open on Mint in a new tab.
- Stock market today: Gift Nifty hints a positive start; eight day trading stocks to buy on Monday, 27 July
Indian stock markets are expected to open higher on Monday, bolstered by positive global cues and declining crude oil prices, which improve investor sentiment. Gift Nifty trades at a premium, signaling a firm domestic start despite previous losses in Nifty 50.
27 Jul 2026 · 4 min read · Mint ↗ - Stock market today:Gift Nifty hints muted start;US tech stocks sell-off, Kospi rebounds to oil prices - 8 stocks to buy
Indian stock market indices Sensex and Nifty 50 are expected to open subdued due to mixed global signals and recent technology stock sell-offs. Investor sentiment remains cautious ahead of US-Iran negotiations, impacting the market outlook amid ongoing volatility in equities.
24 Jun 2026 · 6 min read · Mint ↗
Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →
Frequently Asked Questions
Dr Reddy's Laboratories (NSE: DRREDDY) last traded at ₹1,200.10 on the NSE, down 0.95% (₹11.51) on the day, as of 24 Sep 2026, 9:29 AM. On the BSE it was ₹1,198.60. The day's range was ₹1,196.85 – ₹1,214.35.
Dr Reddy's Laboratories's 52-week high is ₹1,414.40 (29 Jun 2026) and its 52-week low is ₹1,080.05 (23 Jul 2026). At ₹1,200.10 the share is 15.2% below its high and 11.1% above its low.
Dr Reddy's Laboratories's market capitalisation is ₹1,00,040 Cr (₹1.00L Cr). It is part of the NIFTY 50 index.
Dr Reddy's Laboratories's P/E ratio (trailing 12 months) is 35.07. The sector average is 36.50, so investors pay 4% less for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹38.67.
Dr Reddy's Laboratories shares are down 7.43% over the last year, down 4.73% so far this year, down 6.88% over 6 months, down 8.82% over 3 months. Over the last year the stock did 1.57% better than the market.
In FY26 (year to Mar 2026), Dr Reddy's Laboratories reported revenue of ₹33,700 Cr (up 3.24% on the year before) and a net profit of ₹4,196 Cr. Earnings per share were ₹50.35.
Yes. Dr Reddy's Laboratories's latest dividend is ₹8.00 per share (800%, final dividend), with an ex-date of 10 Jul 2026. The dividend yield is 0.66%. It has paid 6 dividends in the records shown on this page.
Of 36 analysts covering Dr Reddy's Laboratories, 13 are bullish (5 strong buy, 8 buy), 9 say hold and 14 are bearish. The consensus is Hold (average rating 2.97 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.
As of Jun 2026: Promoter 26.64%, FII 20.67%, MF 13.16%, Other 39.53%. Promoter holding rose by 0.01 percentage points from Mar 2026.
Dr Reddy's Laboratories's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.